BioSpace News Archive

Drug Development

Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)

VE202 was generally safe and well-tolerated in healthy volunteers, with durable and dose-dependent colonization that will inform the Phase 2 dose regimen

June 9, 2020
·
6 min read
FDA

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial

Amphastar® Pharmaceuticals, Inc., announces that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL Multiple-Dose Vial.

June 9, 2020
·
4 min read
Business

Quotient Limited Provides Update on COVID-19 Antibody Test Progress, Other Key Developments and Fourth Quarter and Full Year Fiscal 2020 Results

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, summarized recent key achievements.

June 9, 2020
·
10 min read
Stilla Technologies Launches the World’s First Six-Color Digital PCR Instrument

Stilla Technologies, a leading provider of digital PCR solutions for high-precision genetic analysis, launched the world’s first six-color digital PCR instrument, the six-color Prism.

June 9, 2020
·
5 min read
BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June 2020

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held on June 25 - 26, 2020.

June 9, 2020
·
3 min read